Austria’s health technology appraisal body, the Ludwig Boltzman Institut, has developed a new methodology for shedding light on how much public funding has been invested in the R&D for high-cost drugs. Better understanding of public contributions could lead to improved pricing policies, says the institute.
Austria Works On Method To Improve Price Transparency
Understanding Public R&D Funding May Lead To Better Pricing Policies
Austria’s health technology appraisal institute aims to further discussion on public investments in R&D and medicines pricing transparency.
More from Europe
More from Geography
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.